Microvast's third quarter was not a miss so much as a rupture in the investment case. The battery maker reported a loss of $0.20 per share, against a $0.04 non-GAAP profit a year earlier, a 600.0% decline in earnings. Revenue of $45.81 million fell 62.8% year over year and missed the $74.2 million consensus by 38.3%. More important than the numbers was the disclosure around them. Management now says there is substantial doubt about the company's ability to continue as a going concern, and that its plans to address that doubt cannot be deemed probable. The narrative has moved from capacity expansion and growth to lender negotiations, cost cuts and preserving liquidity.
The revenue trajectory shows how quickly expectations unraveled. After record fiscal 2025 revenue of $427.5 million, management guided to continued growth in 2026. It called the first quarter's 48% decline temporary and pointed to normalization in the second half. The second quarter's 4.5% dip, helped by 35% growth in Europe, made that framing look plausible. Then the third quarter broke it. Shipments fell to about 190 MWh from roughly 502 MWh. Europe dropped 64% to $27.8 million and APAC fell 65% to $13.5 million, as heavy-duty truck, port equipment and mining customers cut orders. U.S. sales were $4.5 million, against a prior-year period inflated by tariff-driven pull-forward. The growth expectation and the second-half recovery call have both been abandoned.
The quality of the loss deserves scrutiny, but it does not rescue the quarter. GAAP gross margin fell to 5.2% from 37.6%. A $9.3 million write-down of obsolete inventory, largely specialized ESS components, cut 20.4 points from that figure. Even excluding the charge, underlying margin was roughly 25.6%, down from 31.6% in the first quarter and 29.5% in the second, as pricing pressure and poor fixed-cost absorption bit. Operating expenses more than doubled to $69.0 million, driven by $35.7 million of long-lived asset impairments across China, Germany and the U.S. and a $5.1 million litigation provision. The GAAP net loss widened to $76.8 million from $1.5 million.
These charges are non-cash, but they are also an admission that the asset base was built for demand that has not arrived. Adjusted EBITDA swung to negative $60.8 million from positive $3.6 million in the second quarter, and that measure does not strip out the impairments. The cleaner signal is cash. Operating cash burn reached $65.4 million through nine months, roughly double the $33.3 million at the six-month mark. Total cash, including restricted cash, slid to $124.4 million from $143.1 million in June.
The balance sheet is now the central issue. Usable cash was about $71.3 million at October 31. Of the cash and equivalents, $30.4 million sits in China and $14.4 million in Europe, and the company says it currently cannot repatriate those funds to support U.S. operations. Against that, Microvast faces:
- $41.7 million of convertible bonds due by January 31, 2027;
- $84.0 million of short-term PRC bank loans maturing within twelve months;
- a $13.8 million installment due in June 2027.
A missed payment would trigger default and acceleration, along with enforcement of security over its principal Chinese operating subsidiary. The company did retire a $22.4 million facility after quarter-end and refinanced another $8.9 million, so lenders have not walked away. Still, management stressed that outcomes depend on lender decisions outside its control.
The former catalysts have been demoted. Huzhou Phase 3.2 equipment is commissioned, but serial production is now contingent on demand and working capital, and the line is expected to run below design capacity. The Clarksville pack line, once on schedule for year-end output, is now merely substantially completed, with further construction requiring outside financing. The solid-state prototype at 366 Wh/kg is real progress, but management explicitly said it is not commercially ready. Meanwhile, new Chinese consumption taxes on lithium batteries and the loss of export VAT rebates add margin headwinds. A recently acquired European customer adds concentration risk.
The market had been pricing in much of this deterioration before the report. Shares entered earnings at $0.63, down 26.2% since the open after the August report and 53% below the $1.34 200-day average. The stock hit a 52-week low of $0.47 in October, then rebounded about 34% off that level. Investor sentiment flipped from mildly positive (0.19) to negative (-0.12), a meaningful swing. The Earnings Whispers momentum and AVWAP readings remain negative, and Nasdaq listing compliance is an additional overhang.
The bottom line is that Microvast's quarter converted a demand slowdown into a solvency question. The company still has an underlying gross margin in the mid-20s and newly built capacity. But equity holders are now dependent on lender cooperation, a demand recovery management can no longer forecast, and cost cuts that are themselves consuming cash. Until the January bond maturity and the short-term bank lines are resolved, the operating story is secondary.